ACLX 003
Alternative Names: ACLX-003Latest Information Update: 23 Jan 2023
At a glance
- Originator Arcellx
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 13 Jan 2023 Preclinical trials in Acute myeloid leukaemia in USA (Parenteral) (Arcellx pipeline, January 2023)
- 13 Jan 2023 Preclinical trials in Myelodysplastic syndromes in USA (Parenteral) (Arcellx pipeline, January 2023)